This is in line with studies that have shown the capability of renin–angiotensin system inhibitors to modulate glomerular HPSE expression and restore HS in experimental models of metabolic syndrome [54] and in adriamycin nephropathy [55,56]. This evidence concerns the gene REN and metabolic syndrome.